Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...